Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

PrEP science news

Show

From To
Long-acting injectable ARVs are convenient and private, study participants report

HIV-positive people who took injectable cabotegravir + rilpivirine every four or eight weeks as antiretroviral therapy found it more convenient and discreet than daily pills, also feeling

Published
17 January 2018
By
Roger Pebody
To better target HIV prevention, identify people whose social contacts have high viral loads

Rather than relying on assessment of an individual’s sexual behaviour or of ‘community viral load’, targeting of pre-exposure prophylaxis (PrEP) and other prevention interventions could in part

Published
23 November 2017
By
Roger Pebody
Long-acting Injectable Antiretrovirals for PrEP: Will the tail wag the drug?

A medicine you get only every two months to reduce your risk of acquiring HIV sounds like a great deal. And that could be an option in the future. But only if two big efficacy trials of long-acting injectable cabotegravir (CAB-LA) show that it is safe and effective.

Published
09 June 2017
From
AVAC
Bacterial vaginosis does not affect efficacy of oral PrEP in women

Research presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2017) found that the efficacy of oral pre-exposure prophylaxis (PrEP) for women was not affected

Published
23 February 2017
By
Gus Cairns
STI rates in PrEP users very high, but evidence that PrEP increases them is inconclusive

A study of pre-exposure prophylaxis (PrEP) users presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2017) last week in Seattle, showed that PrEP

Published
22 February 2017
By
Gus Cairns
Experimental STI prophylaxis in PrEP users produces big drops in syphilis and chlamydia infections but not in gonorrhoea

Use of the antibiotic doxycycline as on-demand post-exposure prophylaxis by men who have sex with men (MSM) taking part in the Ipergay HIV pre-exposure prophylaxis (PrEP)

Published
15 February 2017
By
Gus Cairns
High hepatitis C prevalence seen in Amsterdam PrEP study participants

Researchers from the Dutch pre-exposure prophylaxis (PrEP) demonstration study, AmPrEP, have found an unexpectedly high rate of hepatitis C virus (HCV) infection in participants tested

Published
06 February 2017
By
Gus Cairns
Men with HIV and men on PrEP in Boston see large increase in sexually transmitted infections

Rates of gonorrhoea, syphilis and chlamydia have risen steeply at Fenway Health in Boston since 2011, according to a presentation last week at IDWeek in New Orleans.

Published
03 November 2016
By
Liz Highleyman
Gay men with overlapping partnerships are more likely to be recently and locally infected

A study analysing transmission patterns between gay men in a cohort of patients in San Diego, California has found the strongest scientific evidence so far that concurrency

Published
06 October 2016
By
Gus Cairns
Vaginal bacteria increase HIV susceptibility and may reduce PrEP effectiveness

Overgrowth of a certain species of vaginal bacteria was associated with a 13-fold higher likelihood of acquiring HIV, while another species was found to lower tenofovir levels

Published
15 August 2016
By
Liz Highleyman

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.